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Full PaperTherapeutic Efficacy of 2-Methoxyestradiol
Microcrystals Encapsulated within
Polyelectrolyte MultilayersSu He Wang,* Xiangyang Shi,* Xisui Chen, James R. Baker Jr.*Development of a novel formulation of anticancer drugs to improve their water-solubility and
bioavailability remains a great challenge. Herein, the potential anticancer agent 2-methoxy-
estradiol (2-ME) was selected as amodel drug andwas encapsulatedwithin polyelectrolyte (PE)
multilayers by layer-by-layer deposition of oppo-
sitely charged PEs onto the drug microcrystal sur-
faces. Cell viability andmorphology observation of
two cell lines reveal that the PE multilayer-encap-
sulated 2-ME microcrystals markedly decrease the
cell viability, displaying similar inhibitory effect
to that of the conventional formulation of 2-ME
dissolved in ethanol. The current approach to
encapsulate hydrophobic drug microparticles
may be useful for formulating different drugs
for a variety of biological applications.Introduction
The layer-by-layer (LbL) self-assembly process is primarily
based on the sequential deposition of oppositely charged
individual polymer layers.[1–3] This technique has been
demonstrated as a powerful tool to construct various
ordered functional thin films,[4] to design diversified
functional capsules, core/shell particles, and hollow
spheres,[5–11] and to encapsulate drug micro- or nanocrys-
tals.[12–19] The driving force to achieve the successful LbL
assembly can be electrostatic interaction,[4] hydrogenS. H. Wang, X. Chen, J. R. Baker Jr.
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 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimbonding,[20–25] covalent interaction,[26,27] and hydrophobic
interaction.[28–30] The physicochemical properties and
stability of the multilayer films may be different when
various driving forces are used to construct the multi-
layers.
Using the LbL self-assembly technique, there are
generally three different approaches for drug encapsula-
tion: (i) loading the drug into preformed LbL-assembled
polymer multilayer capsules;[31–37] (ii) using the drug as a
layer component to assemble it onto colloidal templates
with a polyelectrolyte (PE) through hydrophobic interac-
tion;[28] and (iii) sequentially depositing oppositely charged
PEs onto drug microcrystal surfaces.[18,38] Approach (i) has
been widely studied for in vitro and in vivo cancer
therapeutic and antibiotic applications.[31–34,36,37] In com-
parison with approaches (i) and (ii), approach (iii) allows
higher loading capacity of the drug since the drug micro- or
nanocrystals are encapsulated within PE multilayers.
However, there are only a few reports related to cell
biological or in vivo studies of the drug efficacy when the
drug crystals are encapsulated within PE multilayers.[17,18]DOI: 10.1002/mabi.200800381 429
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430In a previous report, we have shown that 2-methox-
yestradiol (2-ME) (Figure 1), a novel, potential anticancer
drug, can be encapsulated within polymer multilayers
through sequentially depositing dextran sulfate (DS) and
dextran (DN) onto the drug microcrystal surfaces.[18] The
encapsulated 2-ME displays effective drug activity. The
driving force to assemble DS and DN multilayers is
hydrogen bonding. We believe that the formed polymer
capsules may be more stable when the polymer multi-
layers are formed through other stronger driving forces,
e.g., electrostatic interaction.
In this present study, we selected two oppositely
charged PE pairs that can form multilayers through
electrostatic interaction. A biocompatible and biodegrad-
able PE pair (DS and chitosan, CN) and a synthetic PE pair
[poly(sodium 4-styrene sulfonate) (PSS) and poly(allyla-
mine hydrochloride) (PAH)] were selected to form multi-
layers onto 2-ME microcrystal surfaces (Figure 1), respec-
tively. The influence of the polymer biocompatibility and
biodegradability on the drug efficacy was also investigated
using the above PE pairs. The PE multilayer assembly onto
2-ME microcrystals and the hollow shell formation
were confirmed by z-potential measurements, scanning
electron microscopy (SEM), and transmission electron
microscopy (TEM). The 2-ME drug efficacy was tested by
an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide] cell viability assay and by monitoring the
change of cellular morphology. The results will provide a
basis for rational design of drug microcrystal-loaded
polymer multilayer capsules for various biomedical
applications.Figure 1. Molecular structures of 2-ME drug, DPPC, and the used pol
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Materials
DS (Mw ¼500 000), CN with C3646, and minimum 85% deacetyla-
tion, 2-ME, and dipalmitoyl-DL-R-phosphatidylcholine (DPPC)
(Figure 1) were purchased from Sigma. PSS with Mw ¼70 000,
PAH with Mw ¼70 000, and all other chemicals were obtained
from Aldrich and used as received. The water used in all
experiments was passed through a Millipore Milli-Q Plus 185
purification system and had a resistivity exceeding 18.2 MV  cm.Assembly of DS/CN and PSS/PAH Multilayers onto
2-ME Microcrystals
The LbL assembly of DS/CN multilayers onto submicrometer-sized
2-ME crystals was carried out with minor modification from a
published procedure.[18,19] The 2-ME crystals (50 mg) were finely
milled in the presence of 0.25 wt.-% DPPC (2 mL in water), followed
by intense sonication. Then the mixture was diluted with
0.25 wt.-% DPPC to 12 mL and kept for 1 h with occasional
shaking. The resultant product was purified by washing three
times with water and finally resuspended in water. The
precharged crystal particles by DPPC were then LbL-coated with
DS and CN multilayers using a procedure described elsewhere
with slight modifications (In all cases, the PE concentration was
sufficiently higher than that required for saturation coverage of
the crystal particle surface).[19] A 10-mL DS solution (2 mg mL1,
containing 0.5 M NaCl) was added to a 15-mL centrifuge tube
containing 2 mL of the DPPC-coated, dispersed 2-ME crystals. After
adsorption of DS for 15 min, the suspension was centrifuged at
6 000 rpm for 10 min. The supernatant was then removed, and the
coated 2-ME crystals were washed by three alternate cycles ofymers of CN, DS, PAH, and PSS.
DOI: 10.1002/mabi.200800381
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10-mL CN solution (2 mg mL1, containing 0.5 M NaCl) was added
into DS-modified 2-ME crystal suspension and purified in the same
manner. Additional DS/CN multilayers were deposited onto the
microcrystals in the identical fashion until the desired number of
multilayers was achieved. Under similar conditions, PSS/PAH
multilayers were assembled onto 2-ME microcrystal surfaces. The
formed multilayer-encapsulated 2-ME microcrystals were lyophi-
lized on a Labconco system for 2 d and dispersed into PBS buffer
(pH¼7.4) before they were applied for cell biology studies.Hollow Polymer Capsule Production
The 2-ME crystal core was removed by exposing 1 mg of the dried
powder of 2-ME crystal capsules to 1 mL of ethanol for 30 min. The
resultant hollow polymer capsules were then centrifuged at
13 000 rpm for 10 min, washed two times with water, and finally
resuspended in water.z-Potential Measurement
z-potential measurements were performed using a Malvern
Zetasizer Nano ZS model ZEN3600 (Worcestershire, UK) equipped
with a standard 633 nm laser. The 2-ME microcrystals modified
with different layers of PE were dispersed in water before the
measurement.2-ME Loading Capacity Measurement
The loading percentages of 2-ME microcrystal within different PE
multilayer capsules were calculated according to the following
equation:Macrom
 2009Loadingð%Þ ¼ Wd
Wc
 100% (1)where Wc is the mass of the dried PE multilayer-encapsulated
2-ME microcrystals, Wd the mass of 2-ME drugs. The mass of 2-ME
drug crystals in the PE multilayer capsules was determined by
reverse-phase high-performance liquid chromatography (RP-
HPLC). A given amount (0.1–0.5 mg) of dry PE multilayer-
encapsulated 2-ME microcrystals was dissolved in ethanol
according the procedure described above for hollow polymer
capsule production. After centrifugation, the supernatants were
collected for RP-HPLC analysis based on a calibration curve of 2-ME
drug. The RP-HPLC system used in this work consisted of a Waters
Delta 600 separation module, a model 717 auto sampler equipped
with a 100-mL loop, and a model 2996 PDA detector (Waters
Corporation, Milford, MA). A Jupiter C5 silica-based RP-HPLC
column (2504.6 mm2, 300 Å) was purchased from Phenomenex
(Torrance, CA). Two Phenomenex Widepore C5 safety guards
(4 3 mm2) were installed ahead of the Jupiter column. The
mobile phase was a linear gradient beginning with 66:34 v/v
water/acetonitrile (ACN) to 30:70 water/ACN within 20 min at a
flow rate of 1 mL min1. The injection volume was 35 mL. The
detection of eluted samples was performed at 205 nm.ol. Biosci. 2009, 9, 429–436
WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimScanning Electron Microscopy
SEM was carried out with an AMRAY 1910 FE field emission
microscope equipped with a backscattered electron detector at
15 kV. SEM samples (on silicon substrates) were sputter-coated
with about 20 nm Au using a Polaron Sputter Coater system. The
particle size distribution histogram was obtained by measuring
200 individual particles in three different SEM micrographs.Transmission Electron Microscopy
TEM measurements were performed at 60 kV on a Philips CM-100
microscope equipped with a Hamamatsu Digital Camera ORCA-
HR operated using AMT software (Advanced Microscopy Techni-
ques Corp, Danver, MA). TEM samples were prepared by
deposition of a diluted sample suspension (5 mL) onto a carbon-
coated copper grid and air-dried before the measurement.Cell Biological Evaluation
FRTL-5 cells (a rat thyroid epithelial cell line, ATCC, Rockville, MD)
were grown in Ham’s F12 medium containing 10% fetal bovine
serum (FBS) and 15 mIU mL1 of bovine thyroid-stimulating
hormone (TSH, Sigma). KB cells (a human epithelial carcinoma cell
line, ATCC, CLL17, Rockville, MD) were continuously grown in
RPMI 1640 medium supplemented with 10% heat-inactivated FBS,
and 2.5 mM FA. One day before experiments, cells (10 000 cells per
well) were plated into a 96-well plate in a complete medium. The
next day, 2-ME (10 mM) in ethanol solution (1 mL) and 2-ME
microcrystals encapsulated within PE multilayers capsules with
similar 2-ME concentration were added to cells and incubated for
48 h at 37 8C. An MTT assay was used to quantify the viability of
the cells. After 48 h incubation with 2-ME in ethanol solution or
2-ME microcrystals within DS/CN or PSS/PAH multilayer capsules,
the metabolically active cells were then detected by adding MTT to
each well. Then, the plates were read at 570 nm. Mean and
standard deviation for the triplicate wells were reported. After
treatment with 2-ME in ethanol solution or 2-ME microcrystals
within DS/CN or PSS/PAH multilayer capsules, the cell morphol-
ogy was also observed by phase-contrast microscopy (Leica DMIRB
fluorescent inverted microscope). The magnification is set at
200 for all samples.Results and Discussion
The drug 2-ME is present in the serum of women during
the ovulatory and luteal phases of the menstrual cycle and
during pregnancy. As a metabolite of 17-b estradiol, 2-ME
has been demonstrated to be a potential anticancer
agent.[39,40] 2-ME does not display considerable estrogenic
activity at clinically efficacious doses and it does not seem
to promote carcinogenesis. Moreover, it has been found to
be active in inhibiting tumor growth in phase I/II clinical
trials.[41,42] Using the LbL self-assembly technique to
encapsulate the drug 2-ME microcrystals is expected towww.mbs-journal.de 431
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Figure 3. SEMmicrographs of DPPC-modified 2-ME particles coated with (DS/CN)3 (a) and (PSS/
PAH)3 (c) multilayers. (b) and (d) show the size distribution histograms of the (DS/CN)3 and
(PSS/PAH)3 multilayer-encapsulated 2-ME microcrystals, respectively.
432significantly improve the drug solu-
bility in water and its bioavailabil-
ity.
Similar to our previous studies,
the 2-ME drug crystals were finely
milled in the presence of 0.25 wt.-%
DPPC, followed by intense sonica-
tion. This process affords the 2-ME
drug microcrystals to be dispersible
in water and also to be positively
charged.[19] The positive charge of
the 2-ME microcrystals allows sub-
sequent electrostatic LbL assembly
of PSS/PAH and DS/CN multilayers.
Z-potential measurements were
used to monitor each step of the
assembly of 2-ME microcrystals
(Figure 2) with PSS/PAH and DS/
CN multilayers. The alternating
charge reversal (from negative to
positive) of 2-ME microcrystals in
aqueous solution after each layer of
coating with PSS/PAH and DS/CN
pairs indicates the successful elec-
trostatic assembly of PSS/PAH and
DS/CN multilayers. PSS/PAH multi-
layer-coated 2-ME microcrystalsappear to display higher negative and positive surface
potentials than those coated with DS/CN multilayers,
presumably due to the higher charge density of the two
PEs in water.
SEM was used to monitor the surface morphology and
particle distribution of the 2-ME microcrystals coated with
PSS/PAH and DS/CN multilayers. Figure 3a and b show theFigure 2. z-potential of polymer multilayer-encapsulated 2-ME
microcrystals as a function of PE layer number. Layer number
0 indicates the DPPC-modified 2-ME microcrystals.
Macromol. Biosci. 2009, 9, 429–436
 2009 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimSEM micrograph and size distribution histogram of DPPC-
modified 2-ME particles coated with (DS/CN)3 multilayers,
respectively. Similar to our previous observation of DS/DN
multilayer-assembled 2-ME microcrystals,[18] individual
particles display quite different shapes (e.g., cubic,
rectangular, spherical, etc.) with an average size of
3.2 1.4 mm. (PSS/PAH)3 multilayer-assembled 2-ME
particles display similar morphology to those coated with
(DS/CN)3 multilayers (Figure 3c). However, the size of the
(PSS/PAH)3-coated 2-ME particles (1.9 1.1 mm) is much
smaller when compared with those coated with (DS/CN)3
multilayers (Figure 3d). For both cases, the 2-ME particle
size distribution did not change significantly when more
layers of DS/CN or PSS/PAH were deposited onto 2-ME
particle surfaces. Individual bigger particles for both cases
could be related to the aggregation of the 2-ME particles
during the self-assembly process (Figure 3a and c). But this
aggregation did not induce the precipitation of the 2-ME
particles in aqueous solution. The smaller size of PSS/PAH-
coated 2-ME particles may be due to the smaller molecular
weight and the higher charge density of the two polymers
when compared to DS and CN, thereby significantly
prohibiting the possible aggregation of the 2-ME particles
during the self-assembly process. It is interesting to note
that both DS/CN- and PSS/PAH-coated 2-ME particles are
significantly larger in size than those coated with DS/DN
multilayers with a similar layer number through hydrogenDOI: 10.1002/mabi.200800381
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Figure 4. TEM micrographs of (PSS/PAH)3 (a) and (DS/CN)6 (b)
multilayer hollow capsules formed after dissolution of 2-ME
microcrystals in ethanol.bonding interaction in our previous study.[18] It is likely
that the self-assembly through electrostatic interaction
may introduce more aggregation of 2-ME particles than
that formed through hydrogen bonding. Further detailed
mechanistic studies are necessary to confirm this finding.
After exposure of 2-ME particles coated with both PSS/
PAH and DS/CN multilayers to ethanol, hollow capsules
were formed (Figure 4). This further confirms the success-
ful assembly of PSS/PAH and DS/CN multilayers onto 2-ME
microcrystals. For (PSS/PAH)3 hollow capsules (Figure 4a),
the surface of the capsules is distorted with abundant
folds and creases produced by extraction of the solvent in
the PSS/PAH layers prior to the TEM measurement.[3] The
shells composed of PSS/PAH multilayers have a semi-
transparent appearance. DS/CN multilayer capsules with
similar layer number display similar morphology. With
the increase in the layer number, the hollow capsules
with 12 layers of DS/CN are fairly integrated (Figure 4b)
with fewer folds and creases when compared to those with
fewer layers.
The loading percentages of 2-ME microcrystals into
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tals to ethanol for 30 min. The dissolved 2-ME was
analyzed using HPLC. It is clear that the loading percentage
of 2-ME within all PE multilayer capsules with different
composition and layer numbers is quite high within a
range of 50–70% (Table 1). It is reasonable to see that for
both DS/CN and PSS/PAH multilayer capsules, the loading
percentage decreases with the increase in the layer
number. In addition, PSS/PAH multilayer capsules load
more 2-ME microcrystals than DS/CN multilayer capsules
with similar layer number, which is presumably ascribed
to the higher molecular weight and lower charge density
of DS and CN polymers. Compared to a simple geometric
estimation, the practical loading capacity of 2-ME (50–
70%) is rather low. This might be largely due to the
penetration of PE inside the capsules. As mentioned above,
the bigger size of both DS/CN- and PSS/PAH-coated 2-ME
particles (when compared with those coated with DS/DN
multilayers with a similar layer number through hydrogen
bonding interaction in our previous study[18]) is related to
the aggregation of the 2-ME particles during the electro-
static LbL self-assembly process. Consequently, each
micrometer-sized particle could be composed of many
PE-coated nanometer-sized drug particles during the self-
assembly process. The significant amount of PE penetra-
tion inside an entire capsule contributes to a lower loading
efficiency in practice than that estimated theoretically. The
formed 2-ME microcrystals encapsulated within either
PSS/PAH or DS/CN multilayers are very stable in aqueous
solution for at least 9 months. They can also be stored as a
lyophilized form. The dry powder of the 2-ME microcrystal-
containing polymer multilayer capsules can be readily
dispersed in water or PBS buffer for biological studies.
In order to test the drug efficacy of 2-ME microcrystals
encapsulated within PE multilayers, we selected two
different cell lines, FRTL-5 cells, and KB cells. 2-ME exerts its
function through the induction of G2/M cycle arrest of the
cells.[40] The G2/M cycle starts appearing around 48 h after
cell incubation. Therefore, after incubation of the 2-ME
microcrystal-loaded polymer capsules with cells for 48 h,
an MTT assay was performed to evaluate the viability of
FTRL-5 cells (Figure 5) and KB cells (Figure 6) treated with
free 2-ME dissolved in an ethanol solution, and 2-ME
coated with (DS/CN)3; (DS/CN)3DS; (DS/CN)6; (DS/CN)6DS;
(PSS/PAH)3; (PSS/PAH)3PSS; (PSS/PAH)6; and (PSS/PAH)6PSS
multilayers. It appears that both free 2-ME and 2-ME
microcrystal coated with either DS/CN or PSS/PAH multi-
layers with different numbers of layers caused a
significant loss of cell viability in FRTL-5 cells and KB cells
when compared with the untreated corresponding cells.
The ethanol (1 mL) used to dissolve free 2-ME drug does not
exert any favorable influence on the cell viability for both
cells. The cell killing effect of 2-ME microcrystal capsules
on KB cells is much more significant than that on FRTL-5www.mbs-journal.de 433
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Figure 5. MTT assay of FRTL-5 cell viability after treatment with
free 2-ME dissolved in 1 mL ethanol, ethanol (1 mL), 2-ME particles
coated with (DS/CN)3, (DS/CN)3DS, (DS/CN)6, (DS/CN)6DS, (PSS/
PAH)3, (PSS/PAH)3PSS, (PSS/PAH)6, (PSS/PAH)6PSS multilayers for
48 h. The data are expressed as mean S. D.
434cells. This may be due to the fact that KB cell is a human
epithelial cancer cell line, which may grow faster and have
a cell cycle shorter than that of FRTL-5 cells, a normal rat
thyroid cell line. As a cell cycle blocking agent, 2-ME drug
could significantly inhibit the growth of KB cancer cells.
The outermost layer of 2-ME microcrystal capsules
(DS vs. CN or PSS vs. PAH) did not influence the bioactivity
of 2-ME. This finding is to some extent controversial to that
reported by Wang et al.[37] In their study, the drug-loaded
microcapsules were incubated with cells for 2 h, followed
by a washing step to remove the non-adsorbed micro-
capsules. Therefore, microcapsules with positive chargeFigure 6. MTT assay of KB cell viability after treatment with free
2-ME (10 mM) dissolved in 1mL ethanol, 2-ME particles coatedwith
(DS/CN)3, (DS/CN)3DS, (DS/CN)6, (DS/CN)6DS, (PSS/PAH)3, (PSS/
PAH)3PSS, (PSS/PAH)6, (PSS/PAH)6PSS multilayers for 48 h. The
data are expressed as mean S. D.
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can be internalized within cells, while microcapsules with
negative charge are washed away and do not exert any
drug effect. In our case, 2-ME microcrystal capsules with
both positive and negative surface charges were incubated
with cells for 48 h. It is expected that the 2-ME microcrystal
capsules with either positive or negative charge can be
internalized into cell cytoplasm through lipid-raft-
mediated uptake.[43,44] Both DS/CN and PSS/PAH multi-
layers with different number of layers could be dissociated
in the cell plasma, and then 2-ME drugs are released from
the capsules and display cell growth inhibition activity.
For DS/CN multilayers, the polymers are able to degrade at
the cellular environment upon interaction with cells.[45]
The bioactivity of 2-ME microcrystal capsules appears to be
approximately similarly independent of the number of
corresponding polymer layers for each cell lines tested.
Future release kinetics studies may be necessary to help
the complete understanding of the detailed mechanism
related to the therapeutic effect of 2-ME microcrystals
encapsulated within polymer microcapsules. Although the
therapeutic efficacy of 2-ME microcrystal capsules is
different when different cell lines were treated, for a
given cell line, the therapeutic efficacy is more or less
similar, regardless of the biocompatibility and biodegrad-
ability of the coated polymer multilayers (biocompatible
and biodegradable DS/CN multilayers vs. synthetic PSS/
PAH multilayers). Using biocompatible and biodegradable
DS/CN multilayers may be beneficial for future in vivo
studies. In our ongoing studies, the additional toxicity
experiments with different wall materials (including PAH,
PSS, DS, and CN), as well as the toxicity of therapeutically
non-effective 17-b-estradiol microcrystals (used as a
negative control) encapsulated within PSS/PAH and DS/
CN multilayers will be tested. It is likely that the 17-b-
estradiol microcrystals encapsulated within PSS/PAH and
DS/CN multilayers do not display bioactivity, which is a
subject of our further confirmation.
The cytotoxic effect of 2-ME microcrystal capsules was
further confirmed by phase contrast microscopic visuali-
zation of the cell morphology change after treatment with
2-ME with different formulations. Figure 7 shows the
morphology of untreated KB cells, KB cells treated with
2-ME ethanol solution, and 2-ME microcrystals coated with
(DS/CN)3; (DS/CN)6; (PSS/PAH)3PSS; and (PSS/PAH)6PSS
multilayers, respectively. Both 2-ME in ethanol solution
(Figure 7d) and 2-ME microcrystals coated with different
numbers of DS/CN and PSS/PAH multilayers (Figure 7b, c,
e, and f) with similar 2-ME concentration (10 mM) induced
similar cell morphology changes. A significant portion of
the cells became rounded and non-adherent, indicative of
the fact that cells are approaching death (Figure 7). In
contrast, no rounded and detached cells can be visualized
in control cells without 2-ME treatment (Figure 7a). SimilarDOI: 10.1002/mabi.200800381
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Figure 7. Phase-contrast photomicrographs of control KB cells without treatment (a), the same cells treated with free 2-ME (105 M in
ethanol solution) (d), and 2-ME particles coated with (DS/CN)3 (b), (DS/CN)6 (c), (PSS/PAH)3PSS (e), and (PSS/PAH)6PSS (f) multilayers,
respectively.cell morphology changes were observed for FRTL-5 cells
(images not shown), which is consistent with our previous
study.[18]
Using PE multilayer-encapsulated 2-ME microcrystals as
a drug formulation could overcome the water-insolubility
and improve the bioavailability of the drug, similar to our
previous study.[18] It is anticipated that, in in vivo studies,
the side effect should be significantly decreased because of
the protection of polymer multilayers, and the drug
efficacy should be significantly improved because the
crystalline structure of the drug is preserved.[46,47] The
in vitro test of the drug activity did not show clear
advantage of 2-ME microcrystal capsules formed through
electrostatic interaction in comparison to those formed
through hydrogen bonding reported in our previous
study.[18] These differences in the stability of 2-ME
microcrystal capsules formed through different mechan-
isms will be elucidated through future extensive in vivo
studies.Conclusion
In summary, a novel formulation of 2-ME drug has been
developed by sequential deposition of DS/CN or PSS/PAH
multilayers onto DPPC-modified 2-ME microparticles. The
selection of PSS/PAH multilayers was used as a model for
the understanding of the DS/CN multilayers for in vitro
studies of 2-ME drug efficacy, since the pair of PSS/PAH
polymers are not biocompatible for in vivo studies. The
fabrication, morphology, hollow shell formation, and
loading capacity of DS/CN and PSS/PAH multilayer-coated
2-ME particles were extensively investigated usingMacromol. Biosci. 2009, 9, 429–436
 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimz-potential measurements, SEM, TEM, and HPLC. The
formed 2-ME microcrystal capsules with high loading
capacity are bioactive and can inhibit the proliferation of
both a rat thyroid cell line and a human epithelial
carcinoma cell line. We show that 2-ME microcrystal
capsules with different compositions and numbers of
polymer multilayers (DS/CN vs. PSS/PAH) display similar
therapeutic effect to the corresponding cell lines. The
construction of 2-ME microcrystal capsules provides a new
approach to develop formulations of various hydrophobic
anticancer drugs for therapeutic as well as other pharma-
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17, 5375.
[16] A. S. Zahr, M. de Villiers, M. V. Pishko, Langmuir 2005, 21, 403.
[17] A. S. Zahr, M. V. Pishko, Biomacromolecules 2007, 8, 2004.
[18] X. Shi, S. Wang, X. Chen, S. Meshinchi, J. R. Baker, Mol.
Pharmaceutics 2006, 3, 144.
[19] X. Shi, F. Caruso, Langmuir 2001, 17, 2036.
[20] H. Zhang, Z. Wang, Y. Zhang, X. Zhang, Langmuir 2004, 20,
9366.
[21] D. M. DeLongchamp, P. T. Hammond, Langmuir 2004, 20,
5403.
[22] Y. Fu, S. Bai, S. Cui, D. Qiu, Z. Wang, X. Zhang, Macromolecules
2002, 35, 9451.
[23] Z. Liang, O. M. Cabarcos, D. L. Allara, Q. Wang, Adv. Mater.
2004, 16, 823.
[24] J. F. Quinn, F. Caruso, Langmuir 2004, 20, 20.
[25] Y. Tian, Q. He, Y. Cui, C. Tao, J. Li, Chem. Eur. J. 2006, 12, 4808.
[26] Z. Liang, Q. Wang, Langmuir 2004, 20, 9600.
[27] L. Duan, Q. He, X. Yan, Y. Cui, K. Wang, J. Li, Biochem. Biophys.
Res. Commun. 2007, 354, 357.
[28] Z. F. Dai, A. Voigt, S. Leporatti, E. Donath, L. Dahne, H.
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